FDA Approves Coya Therapeutics’ Trial of COYA 302 for ALS

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS

FDA approves Coya Therapeutics’ trial of COYA 302 for ALS

Coya Therapeutics has announced the acceptance by the US FDA of IND application for COYA 302, paving the way for a Phase II trial.The post FDA approves Coya Therapeutics’ trial of COYA 302 for ALS appeared first on Clinical Trials Arena.

COYA 302 Heads to Phase 2 Trial of ALS Following IND Acceptance

The FDA has accepted the IND for COYA 302, a Treg-targeting combination therapy for ALS, clearing the way for a pivotal phase 2 multicenter trial.